NextCell Pharma AB

NextCell Pharma AB is a Swedish biotechnology company developing advanced stem cell therapies primarily for autoimmune and inflammatory diseases. Headquartered in Huddinge, Sweden. Here are key aspects of the company:

• Products & Services: The company develops three business areas—ProTrans (a therapy candidate using allogeneic mesenchymal stromal cells from umbilical cord Wharton's Jelly for respiratory complications related to COVID-19 and Type 1 diabetes), Cellaviva (Skandinaviens största stamcellsbank, or Scandinavia's largest stem cell bank), and QVance.
• Innovation & Technology: ProTrans is built on NextCell's patented selection algorithm. The company focuses on the development of advanced therapy medicinal products (ATMPs).
• Customers & Industries Served: Initial focus includes treating Type 1 diabetes, with a Phase II study for respiratory complications at COVID-19 accepted for publication in Cytotherapy, the official scientific journal of the International Society for Cell & Gene Therapy (ISCT). NextCell Pharma AB is known for its role as a Swedish biotech firm driving stem cell revolution through proprietary therapies and operating Scandinavia's largest stem cell bank.